May 17, 2020

Viagra pharma website in Google+ email invitation scam

Viagra
pharmaceutical
website
Google+ invitations
Admin
2 min
Google+
Fake email invitations for the newly launched Google+ social networking site are leading internet surfers to pharmaceutical website. It is thought the...

Fake email invitations for the newly launched Google+ social networking site are leading internet surfers to pharmaceutical website.

It is thought the internet giant’s new project has become the victim of a hacking group, who are inviting people to join the social network but instead direct them to an online Viagra-selling store.

The pharmaceutical website is Canadian, leading to speculation that the hacking group is also from Canada and there are thoughts that it could be the work of the Partnerka organisation.

READ MORE FROM THE WDM CONTENT NETWORK:

To read the latest edition of Healthcare Global, click here

The scam was uncovered by Sophos, an internet security firm who is branding the scam as ‘amateur’.

“This group is trying to lure uses to a pharmaceutical website by using Google+ invites,” explains Graham Cluley, a senior technology consultant at Sophos.

“The scam is still ongoing and spreading around the world,” he said, adding: “The scam is quite amateur at this stage as the link doesn’t even take the user to a Google-looking site from which the hackers could then grab personal details.

“It just takes you directly to the wrong site and most people won’t fall for it – but they should still be careful and check the identity of the person supposedly sending them the invite to join Google+.”

A trial of Google+ was launched last week and people have to be invited to join the social networking site by current users. 

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article